Meeting
2019 Genitourinary Cancers Symposium
The role of enzalutamide-induced hyperactive Jak2-Stat5 feed-forward signaling loop on enzalutamide-resistant prostate cancer growth and as a therapeutic target for second-line treatment.
Authors
Vindhya Udhane
Medical College of Wisconsin, Wauwatosa, WI
Vindhya Udhane , Cristina Maranto , David Hoang , Andrew Erickson , Savita Devi , Kenneth Jacobsohn , Kenneth Iczkowski , William See , Deepak Kilari , Tuomas Mirtti , Marja Nevalainen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 221)
DOI
10.1200/JCO.2019.37.7_suppl.221
Abstract #
221
Poster Bd #
J22
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
The impact of TAS3681, a new type of androgen receptor antagonist, on aberrant AR signaling that drives tumor resistance to AR-targeted therapies by down-regulating full length and splice variant AR.
First Author: Daisuke Kajiwara
Poster
2016 ASCO Annual Meeting
Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Poster
2015 Genitourinary Cancers Symposium
Dual targeting of the androgen receptor and hypoxia-inducible factor-1α pathways to synergistically inhibit castrate-resistant prostate cancer.
First Author: William Douglas Figg
Poster
2024 ASCO Genitourinary Cancers Symposium
Lipidomic profiling as a biomarker for prostate cancer diagnosis and response to enzalutamide (Enza).
First Author: Sara Bleve